Amelioration of diabetic nephropathy by oral administration of d-α-tocopherol and its mechanisms. Issue 1 (2nd January 2018)

• Record Type: Journal Article
• Authors: Hayashi, Daiki; Ueda, Shuji; Yamanoue, Minoru; Ashida, Hitoshi; Shirai, Yasuhito
• Is Part Of: Bioscience, biotechnology, and biochemistry. Volume 82:Issue 1(2018)
• Page Start: 65
• Page End: 73
• Publication Date: 2018-01-02
• Subjects: Diabetic nephropathy -- diacylglycerol kinase -- d-α-tocopherol -- protein kinase C; Biotechnology -- Periodicals; Biochemistry -- Periodicals; 660.6
• DOI: 10.1080/09168451.2017.1411184
• Languages: English
• ISSNs: 0916-8451

Abstract

Abstract: Diabetic nephropathy (DN) is a diabetic vascular complication, and abnormal protein kinase C (PKC) activation from increased diacylglycerol (DG) production in diabetic hyperglycemia is one of the causes of DN. Diacylglycerol kinase (DGK) converts DG into phosphatidic acid. In other words, DGK can attenuate PKC activity by reducing the amount of DG. Recently, we reported that intraperitoneally administered d-α-tocopherol (vitamin E, αToc) induces an amelioration of DN in vivo through the activation of DGKα and the prevention of podocyte loss. However, the effect of the oral administration of αToc on DN in mice remains unknown. Here, we evaluated the effect of oral administration of αToc on DN and its molecular mechanism using streptozocin-induced diabetic mice. Consequently, the oral administration of αToc significantly ameliorated the symptoms of DN by preventing the loss of podocytes, and it was revealed that the inhibition of PKC activity was involved in this amelioration. Abstract: : The assumed mechanisms of the protective effect of d-α-tocopherol on diabetic nephropathy.